{"filing":{"accession_number":"0001062993-26-002787","cik":"0001728328","ticker":null,"company_name":"InMed Pharmaceuticals Inc.","form":"8-K","filing_date":"2026-05-19","report_date":null,"primary_document":"form8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1728328/000106299326002787/form8k.htm"},"classifications":[{"id":53,"accession_number":"0001062993-26-002787","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"The Company amended preferred investment options with Armistice Capital, dramatically reducing the exercise price from $16.60 to $0.80 per share on 278,761 common shares. This substantial downward repricing of equity warrants significantly increases the likelihood of exercise and dilution to existing shareholders, making it a material dilutive event. The amendment effectively converts out-of-the-money options into deeply in-the-money instruments, which is a classic signal of dilutive equity issuance activity.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-20T02:13:53.287827+00:00","company_name":"InMed Pharmaceuticals Inc.","ticker":null,"filing_date":"2026-05-19"},{"id":54,"accession_number":"0001062993-26-002787","item_number":"3.03","item_title":"Material Modification to Rights of Security Holders.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.45,"reasoning":"Item 3.03 discloses a material modification to security holders' rights and incorporates Item 1.01 by reference. Item 1.01 typically covers entry into a material agreement or plan of acquisition, merger, or disposition. Without access to the full Item 1.01 content, the specific nature of the modification cannot be determined; however, the cross-reference signals a material event affecting shareholder rights that does not fit neatly into the more specific event categories (e.g., it may involve a restructuring, recapitalization, or other corporate action).","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-20T02:13:53.287827+00:00","company_name":"InMed Pharmaceuticals Inc.","ticker":null,"filing_date":"2026-05-19"},{"id":55,"accession_number":"0001062993-26-002787","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.65,"reasoning":"The filing discloses an amendment to the \"Armistice Preferred Investment Options\" announced via press release on May 19, 2026. While the specific terms and materiality of the amendment are not detailed in the Item 8.01 text itself, amendments to preferred investment arrangements with a named counterparty (Armistice) typically signal a material modification to the company's capital structure or financing terms. Without clearer language indicating this is a routine administrative matter, and given the formal press release announcement, this is classified as a material event that does not fit neatly into more specific categories (e.g., not a dilutive issuance, not M\u0026A, not compensation).","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-20T02:13:53.287827+00:00","company_name":"InMed Pharmaceuticals Inc.","ticker":null,"filing_date":"2026-05-19"}]}